Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: web + 0.27  Related to the article below (Last Update: 8/4/2008)

Salix Pharmaceuticals Reports 2Q2008 Results
FOXBusiness -
Interested parties can access the conference call by way of web cast or telephone. The live web cast will be available at www.salix.com. A replay of the web ...SLXP
Orbotech Announces Second Quarter 2008 Results
FOXBusiness -
A live web cast of the conference call and a replay can also be heard by accessing the investor relations section on the Company's website at ...ORBK - FRA:ORBK

Earthtimes (press release)
Equity One Reports Second Quarter 2008 Operating Results
WELT ONLINE, Germany - Jul 29, 2008
CONFERENCE CALL/WEB CAST INFORMATION We will host a conference call on Wednesday, July 30, 2008, at 9:00 am EST to review the 2008 second quarter earnings ...
Highwoods Properties Reports Second Quarter 2008 Results Trading Markets (press release)
all 206 news articles »  EQY - HIW - COL:EQIT

WELT ONLINE
Aladdin Knowledge Systems Reports Second Quarter 2008 Financial ...
MarketWatch - Jul 21, 2008
Released Aladdin eSafe v6.2 Proxy, offering organizations more options in control and flexibility for secure Web gateway deployment. ...
Illumina Reports Financial Results for Second Quarter 2008 FOXBusiness
ESI Announces First Quarter Fiscal 2009 Results MarketWatch
BMC Software Announces Fiscal 2009 First Quarter Results MarketWatch
all 773 news articles »  ALDN - BMC - ILMN
Tetra Tech Reports Record Third Quarter Results Exceeding Revenue ...
WELT ONLINE, Germany - Jul 30, 2008
... net of tax ? ? ? ? Net income $ 0.27 $ 0.21 $ 0.72 $ 0.55 Weighted average common shares outstanding: Basic 58943 58030 58590 57859 Diluted 59833 58786 ...TTEK
Power-One Announces Second Quarter 2008 Results
MarketWatch - Jul 24, 2008
The call will be available over the Internet through the Company's investor relations Web site at www.power-one.com. To listen to the call, please go to the ...PWER

Earthtimes (press release)
Investor Relations Earnings Release
MarketWatch - Jul 31, 2008
0.27 0.54 Components of change -- 2008 vs. 2007 Higher natural gas margins........ 0.02 0.05 Higher allowance for funds used during construction - equity. ...
Chicopee Bancorp, Inc. Reports Second Quarter Results FOXBusiness
Banner Corporation Announces Second Quarter Results; Includes ... MarketWatch
all 1,045 news articles »  XEL - CBNK - BANR

Earthtimes (press release)
Xantrex(TM) Technology Inc. Reports 2008 Second Quarter
MarketWatch - Jul 29, 2008
Our complete second quarter 2008 Management's Discussion and Analysis and Financial Statements are available on the Xantrex web site at www.xantrex.com. ...
Polypore Reports Strong Second Quarter Sales and Earnings Growth Primenewswire (press release)
Mothers Work Reports Third Quarter Fiscal 2008 Earnings Earthtimes (press release)
all 859 news articles »  TSE:XTX - MWRK - PPO
Auxilium Pharmaceuticals, Inc. Announces Second Quarter 2008 ...
CNNMoney.com - Jul 31, 2008
The net loss for the second quarter of 2008 was $11.7 million, or $(0.29) per share, compared to a net loss of $10.0 million, or $(0.27) per share, ...AUXL
OTC ADVISORS, LLC: (OTCBB:TOGI), (Pinksheets:FFGO), (OTCBB:NEOM)
Trading Markets (press release), CA - Aug 1, 2008
Similarly, Alta Gold intersected 20 feet of 0.27 oz/ton gold at 345 feet. Based on historical data from near-surface exploration of past programs, ...OTC:TOGI - OTC:NEOM - OTC:CMTX
Source: Google News

Measuring the Independence of Central Banks and Its Effect on Policy Outcomes -
A Cukierman, SB Web, B Neyapti - The World Bank Economic Review, 1992 - World Bank
... Legal central bank in- depen- dence" (index) of 0.69 0.64 0.61 0.50 0.48 0.45 0.44
0.42 0.36 0.34 0.33 0.29 0.28 0.27 0.25 0.24 0.24 0.23 0.18 0.17 0.17 ...

Web caching and Zipf-like distributions: evidence and implications -
L Breslau, P Cao, L Fan, G Phillips, S Shenker - INFOCOM'99. Eighteenth Annual Joint Conference of the IEEE …, 1999 - ieeexplore.ieee.org
... Questnet NLANR L0.04 -0.08 0.003 -0.04 -0.02 -0.09 DEC UPisa FuNet UCB Questnet
NLANR -0.19 -0.27 0.005 0.002 -0.03 -0.08 the total number of web documents, q ...

TERRESTRIAL?AQUATIC LINKAGES: RIPARIAN ARTHROPOD INPUTS ALTER TROPHIC CASCADES IN A STREAM FOOD WEB -
S Nakano, H Miyasaka, N Kuhara - Ecology, 1999 - JSTOR
... benthic community by altering the intensity of fish predation in the stream's food
web. ... 1.2 31.7 + 1.0 31.1 0.9 34.6 1.2 Discharge (m3/s) 4 0.27 + 0.01 0.26 ...

System and method for producing a bleached cotton, nonwoven web -
WG Ripley - US Patent 5,634,243, 1997 - freepatentsonline.com
... The final non-woven web, consisting of bleached cotton fibers, may be made into
highly ... International Classes: D01G 021/00; 302; 304; 297; 105; 0.27; 150; 151. ...

Consumer reactions to electronic shopping on the world wide web
SL Jarvenpaa, PA Todd - International Journal of Electronic Commerce, 1996 - portal.acm.org
... Shopping on the World Wide Web ... ABSTRACT: Much fascination and speculation surrounds
the impact of the World Wide Web on consumer shopping behavior. ...

[PDF] Web response time and proxy caching -
B Liu, G Abdulla, T Johnson, EA Fox - Proceedings of WebNet98, November, 1998 - pubs.dlib.vt.edu
... time Workloads Connection Time Elapsed Time Ratio American Online 0.5385 1.9824
0.27 ... This result suggests that a Web client?s default timeout value should ...

Harvesting implicit group attitudes and beliefs from a demonstration web site -
BA Nosek, MR Banaji, AG Greenwald - Group Dynamics: Theory, Research, and Practice, 2002 - content.apa.org
... measure, the magnitude of that effect was noticeably smaller (ds 0.27 and 0.36 ... limited
in the availability of Black American subjects, and hence Web data are of ...

A Meta-Analysis of Response Rates in Web-or Internet-Based Surveys -
C Cook, F Heath, RL Thompson - Educational and Psychological Measurement, 2000 - epm.sagepub.com
... For these populations, e-mail and Web surveys may have only minor coverage ... 0.27
0.45 ?.336 .332 ?.333 ?.210 ?.342 .093 .175 .054 ?.048 ?.152 ...

[PDF] WebQual: a measure of Web site quality
ET Loiacono, RT Watson, DL Goodhue - 2002 Marketing Educators? Conference: Marketing Theory and …, 2002 - terry.uga.edu
Page 1. 1 WebQual?: A Measure of Web Site Quality Eleanor T. Loiacono ... 0037
Page 2. 2 WebQual?: A Measure of Web Site Quality Eleanor T ...

The role of experience in web-building spiders (Araneidae)
AM Heiling, ME Herberstein - Animal Cognition, 1999 - Springer
... sclopetarius SS df F P A. keyserlingi (n = 13) Web area-asymmetry Web number
0.27 5 2.73 0.03 Treatment 0.39 1 6.84 0.02 CTL-asymmetry ...

Source: Google Scholar
 
 

Nanoparticles Used By U-M Researchers To Target Brain Cancer

Article Date: 21 Nov 2006 - 21:00pm (PST)
Tiny particles one-billionth of a meter in size can be loaded with high concentrations of drugs designed to kill brain cancer. What's more, these nanoparticles can be used to image and track tumors as well as destroy them, according to researchers at the University of Michigan Comprehensive Cancer Center.

Researchers incorporated a drug called Photofrin along with iron oxide into nanoparticles that would target cancerous brain tumors. Photofrin is a type of photodynamic therapy, in which the drug is drawn through the blood stream to tumor cells; a special type of laser light activates the drug to attack the tumor. Iron oxide is a contrast agent used to enhance magnetic resonance imaging, or MRI.

"Photofrin goes into tumor blood vessels and collapses the vasculature, which then starves the tumor of the blood flow needed to survive. The problem with free photofrin therapy is that it can cause damage to healthy tissue. In our study, the nanoparticle becomes a vehicle to deliver the drug directly to the tumor," says study author Brian Ross, Ph.D., professor of radiology at the U-M Medical School and co-director of Molecular Imaging at the U-M Comprehensive Cancer Center.

Article continues below and (thank you)
 
Photofrin has been used to treat several types of cancer, including esophageal, bladder and skin cancers. It works by traveling through blood vessels until it reaches the vessels supplying blood to the tumor. When activated by light, the Photofrin collapses these blood vessels, starving the tumor of the blood it needs to survive.

Results of the study appear in the Nov. 15 issue of Clinical Cancer Research.

"Thinking outside the box is a must for developing brain cancer treatments. Drugs don't get into the brain when delivered in the normal way, which explains in part why some current treatments for brain tumors are generally not effective. Targeting the tumor vasculature with nanoparticles containing a payload will overcome these issues," says study author Alnawaz Rehemtulla, Ph.D., professor of radiology and radiation oncology at the U-M Medical School and professor of environmental health sciences at the School of Public Health.

Treating brain tumors is traditionally difficult because of the blood-brain barrier, which prevents harmful substances from traveling through the bloodstream into the brain. In order for chemotherapy to treat a tumor, it must penetrate this barrier.
 
Researchers tested the nanoparticles in cell cultures and animal models. The studies showed the nanoparticles traveled to the tumor, resulting in less Photofrin exposure throughout the body and enhanced exposure within the tumor. This allowed a larger window for activating the drug with light. It also would eliminate a common side effect of photodynamic therapy, in which healthy skin becomes sensitive to light.

In rat studies, researchers found those treated traditionally with Photofrin survived 13 days, while rats treated with Photofrin incorporated into a nanoparticle survived an average of 33 days. Forty percent of the rats remained disease-free six months after treatment.

The researchers also found twice the amount of the contrast agent at the tumor site when using targeted nanoparticles, suggesting the nanoparticles were attracted to the tumor site.

The advantage of this delivery system is the ability to attack the tumor with higher doses of a drug while sparing normal tissue from a drug's toxic side effects.

"Our research suggests that you can take a drug that may be toxic to normal tissue - it could be any type of drug, not just photodynamic - and you could deliver higher doses of that drug for a more powerful punch," says Rehemtulla, co-director of Molecular Imaging at the U-M Comprehensive Cancer Center.

If nanoparticle delivery proves to be safe in humans, it will allow researchers to re-examine previously developed drugs that were discarded because they caused too many dangerous side effects in patients.

By combining the drug with a contrast agent, researchers were able using imaging techniques to determine whether the drug actually got to the tumor. This technique could have potential to diagnosis brain tumors early, as well as to help researchers determine when to deliver a drug or when to administer the next dose.

Further lab research is needed before the nanoparticle technology can be tested in clinical trials. More than 18,800 people will be diagnosed with brain cancer this year, and 12,820 will die from it. For information about treatments that are currently available, call U-M's Cancer AnswerLine at 800-865-1125.

###

For more information, contact: Sally Pobojewski

In addition to Ross and Rehemtulla, study authors are Mahaveer Bhojani, Bradford Moffat, Daniel Hall, Michael J. Woolliscroft, and James V. Sugai, all from the U-M Center for Molecular Imaging; G. Ramachandra Reddy from Molecular Therapeutics Inc.; Patrick McConville and Jonathan Moody, both from Molecular Imaging Research Inc.; Gwangseong, Yong-Eun Koo and Raoul Kopelman, all from the U-M Department of Chemistry; Timothy D. Johnson from the Department of Biostatistics; and Martin A. Philbert from the Department of Toxicology.

Funding for the study was from National Cancer Institute. The University of Michigan has filed for patent protection on this nanoparticle delivery technology and has licensed the commercialization rights to MIRROR Inc., a wholly-owned subsidiary of Molecular Therapeutics Inc. of Ann Arbor. Should this partnership result in products reaching market, the University and the individual inventors of this technology, including Ross and Rehemtulla, stand to benefit financially.

Reference: Clinical Cancer Research, vol. 12, issue 22.

Contact: Nicole Fawcett
University of Michigan Health System
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With: News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 
 © 2002-2006

Keywords::

Contact Iconocast

Home Page